Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).

Andrzej Jakubowiak,Agnes Benedict,Sumeet Panjabi,Ivan Houisse,Marco Campioni,Andromachi Giannopoulou,Sanjay Aggarwal,Rafael Fonseca

Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).

2016

Andrzej Jakubowiak
Agnes Benedict
Sumeet Panjabi
Ivan Houisse
Marco Campioni
Andromachi Giannopoulou
Sanjay Aggarwal
Rafael Fonseca

8021Background: In ASPIRE, KRd achieved superior progression free survival (PFS) (HR = 0.69; p = 0.0001) and improved quality of life (QoL) (p < 0.001) over Rd in patients (pts) with R/RMM. We asse...

Keywords:

Refractory Multiple Myeloma
Dexamethasone
Oncology
Lenalidomide
Pathology
Carfilzomib
Internal medicine
Medicine
Quality of life
in patient
Progression-free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations